A randomized trial of early intravesical instillation of epirubicin in superficial bladder cancer

1994 ◽  
Vol 35 (S1) ◽  
pp. S31-S35 ◽  
Author(s):  
Kikuo Okamura ◽  
Tatsuro Murase ◽  
Koji Obata ◽  
Shinichi Ohshima ◽  
Yoshinari Ono ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Randomized Trial ◽  
Superficial Bladder Cancer ◽  
Intravesical Instillation

882: Intravesical Instillation of Liposomal Doxorubicin Nanoparticles in Mouse Superficial Bladder Cancer

2007 ◽  
Vol 177 (4S) ◽  
pp. 293-293
Author(s):  
Satoshi Anai ◽  
Atsushi Tomioka ◽  
Yoshihiko Hirao ◽  
Ikumi Sugiyama ◽  
Yasuyuki Sadzuka ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Liposomal Doxorubicin ◽  
Superficial Bladder Cancer ◽  
Intravesical Instillation

Phase II Marker Lesion Study With Intravesical Instillation of Apaziquone for Superficial Bladder Cancer: Toxicity and Marker Response

2006 ◽  
Vol 176 (4) ◽  
pp. 1349-1353 ◽  
Author(s):  
Antoine G. van der Heijden ◽  
Paula M.J. Moonen ◽  
Erik B. Cornel ◽  
Henk Vergunst ◽  
Theo M. de Reijke ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Phase Ii ◽  
Superficial Bladder Cancer ◽  
Intravesical Instillation

scholarly journals Analysis of Japanese Patients Treated with or without Long-Term Epirubicin Plus Ara-C Intravesical Instillation Therapy for Low-Grade Superficial Bladder Cancer

2015 ◽  
Vol 2015 ◽  
pp. 1-5 ◽  
Author(s):  
Tomonori Kato ◽  
Kazushi Nomura ◽  
Fukuo Kondo ◽  
Masami Wakisaka ◽  
Akira Komiya
Keyword(s):  
Bladder Cancer ◽  
Tumor Recurrence ◽  
Superficial Bladder Cancer ◽  
Transitional Cell ◽  
Japanese Patients ◽  
Intravesical Instillation ◽  
Intravesical Chemotherapy ◽  
Low Grade ◽  
Free Rate

The high incidence of tumor recurrence following transurethral resection (TUR) represents a major problem encountered in the management of bladder cancer. This study examined the efficacy of intravesical chemotherapy in superficial bladder cancer. We retrospectively analyzed 90 Japanese cases with low-grade superficial transitional cell carcinoma (stage T1, grades 1 and 2) who were rendered tumor-free by TURBT (TUR of bladder tumor) and who thereafter were treated with or without intravesical chemotherapy. Among them, instillation was terminated in 2 patients due to adverse effects (severe but reversible chemical cystitis). Remaining 88 patients were divided into 2 groups according to therapy: the TURBT-only group(n=46), defined as patients treated with TURBT alone, and the Instillation group(n=42), defined as patients treated with weekly intravesical instillation therapies using epirubicin plus Ara-C. Recurrence-free rate was significantly higher in the Instillation group than in the TURBT-only group (p=0.02, HR = 0.457). The 5-year recurrence-free rate was 58.5% for the Instillation group and 38.6% for the TURBT-only group. Our instillation schedule represents the most intensive regimen among previously reported therapies and resulted in a 54.3% decrease in incidence of tumor recurrence. We believe that the results of this study could provide useful information on management of bladder cancer.

Sign in / Sign up

Export Citation Format

Share Document